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OutbreakMumps virus (MuV) causes acute infections in humans. In recent years, MuV has caused epidemics among
highly vaccinated populations. The largest outbreak in the U.S. in the past 20 years occurred in 2005–2006
with over 5000 reported cases in which the majority of the cases was in vaccinated young adults. We
sequenced the complete genome of a representative strain from the epidemic (MuV-IA). MuV-IA is a member
of genotype G, the same genotype of MuV that was associated with the outbreak in the UK in 2004–2005. We
constructed a reverse genetics system for MuV-IA (rMuV-IA), and rescued a virus lacking the open reading
frame (ORF) of the SH gene (rMuVΔSH). rMuVΔSH infection in L929 cells induced increased NF-κB activation,
TNF-α production and apoptosis compared to rMuV-IA. rMuVΔSH was attenuated in an animal model. These
results indicated that the SH ORF of MuV plays a signiﬁcant role in interfering with TNF-α signaling and viral
pathogenesis during virus infection.Diseases, College of Veterinary
thens, GA 30602, USA.
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Mumps virus (MuV) is a member of the family Paramyxoviridae.
MuV causes acute parotitis in humans, characterized by lateral or
bilateral swelling of the salivary glands (Carbone and Wolinsky,
2001). MuV is also notable as a neurotropic agent causing a number of
central nervous system (CNS) manifestations ranging from mild
meningitis to severe encephalitis. The incidence of mumps and its
complications were dramatically reduced following the introduction
of measles, mumps, rubella vaccine (MMR) in 1971 (Amexis et al.,
2002; Carbone and Wolinsky, 2001). MMR vaccine containing the
Jeryl Lynn (JL) strain, an attenuated strain of MuV, is highly efﬁcacious
and produces few adverse reactions.
In spite of high coverage with MMR, mumps outbreaks continue to
occur in the US and other countries. The causes cited range from
failure to vaccinate, vaccine failure, and emergence of strains of MuV
capable of escaping vaccine-induced immunity (Crowley and Afzal,
2002; Lim et al., 2003; Otto et al., 2010; Strohle et al., 1996; Utz et al.,2004; Whelan et al., 2010). In 2006, the U.S. experienced the largest
mumps epidemic in nearly 20 years (Marin et al., 2008). The outbreak
originated at a university in Iowa and spread to 11 other states. Over
5000 mumps cases were reported in 2006 compared to an average of
approximately 250 cases/year in the previous decade. In 2009–2010, a
mumps outbreak occurred in the State of New York and the State of
New Jersey in the US in which 88% of the patients had one-dose of
mumps vaccine and 75% of the patients had two doses of vaccine
(MMWR, 2010).
The SH gene of MuV is themost variable region in mumps genome.
Based on the sequence variability of the SH protein, all current wild
type MuVs have been classiﬁed into 12 genotypes (Jin et al., 2005).
Sequence comparison of the SH proteins from the outbreaks indicated
that both Iowa and New Jersey/New York outbreaks were caused by
closely related mumps strains in genotype G. Interestingly, the
genotype G viruses detected in the outbreaks in the U.S. were also
closely related to mumps virus strains associated with the massive
mumps epidemic in the UK in which over 56,000 cases were reported
in the 2004–2005 (MMWR, 2006; Rota et al., 2009; Watson-Creed et
al., 2006).
MuV, a paramyxovirus, is a negative stranded, non-segmented
RNA virus with a genome of 15,384 nucleotides (Carbone and
Wolinsky, 2001). The virus has seven genes but encodes nine
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(P) and large RNA polymerase (L) protein are important for
transcription and replication of the viral RNA genome (Elango et al.,
1988; Okazaki et al., 1992; Rima et al., 1980). The V/P gene encodes
three proteins, I, V and P (Paterson and Lamb, 1990). Mutations in the
P gene have been associated with increased virulence of mumps virus
(Saito et al., 1996). The V protein plays important roles in inhibiting
interferon signaling in infected cells (Kubota et al., 2002; Takeuchi et
al., 1990; Ulane et al., 2003; Yokosawa et al., 2002). The fusion (F)
protein, a glycoprotein, mediates both cell-to-cell and virus-to-cell
fusion in a pH-independent manner that is essential for virus entry
into cells (Waxham et al., 1987). The hemagglutinin-neuraminidase
(HN), another viral glycoprotein, is also involved in virus entry
(Tanabayashi et al., 1992) and mutations in the HN gene have
been implicated in mumps virus virulence (Cusi et al., 1998). The
matrix (M) protein plays an important role in virus assembly
(Matsumoto, 1982). The small hydrophobic (SH) protein is a 57-
residue type 1, hydrophobic integral membrane protein (Elango et
al., 1988). It has been reported that MuV SH has a similar function
to the SH protein of a closely related virus, parainﬂuenza virus 5
(PIV5, formerly known as simian virus 5, SV5) (Hiebert et al.,
1988; Wilson et al., 2006). While the SH ORF of PIV5 is not
essential for virus growth in tissue culture cells, a virus lacking SH
induces higher levels of cell death and is attenuated in an animal
model (He et al., 1998, 2001). SH of PIV5 inhibits TNF-α signaling
(Lin et al., 2003; Wilson et al., 2006). However, the expression of
the SH protein in cells infected with MuV has never been
demonstrated and the role of SH has never been reported. In
this work, we have generated a reverse genetics system based on a
representative isolate from the outbreak in 2006 in the U.S. and
studied the biologic properties of a rescued recombinant virus
lacking the SH ORF. These results indicated that MuV SH ORF plays
a role in interfering with TNF-α signaling during virus infection.Results
Sequence of the complete genome of MuV-IA
To better understand the genetic characteristics of viruses
associated with recent outbreaks in the U.S., the complete genomic
sequence of a representative isolate from the Iowa outbreak was
determined (JN012242). A set of primers was designed based on the
consensus sequence derived from comparison of the genomic
sequences of Jeryl Lynn, Urabe, 88–1961 and PetroNov. Viral RNA of
MuV-IA was reverse-transcribed into cDNA using random hexamers,
PCR reactions were then carried out using the set of primers and the
products were sequenced using the corresponding primers. A second
set of primers based on the sequencing results were then used to
performRT-PCR and the products overlappingwith those ofﬁrst round
of sequencing fragments were sequenced using the primers. Leader
and trailer sequences were determined by performing 5′/3′ RACE.
There is only one conserved change in the putative transmem-
brane domain of the SH protein when the SH protein sequence of
MuV-IA was compared to other strains of mumps virus in genotype G
(Fig. 1A), conﬁrming that MuV-IA belongs to genotype G (Rota et al.,
2009). To further study the genomic divergence of MuV-IA, a
phylogenetic tree was generated using the genomic sequence of
MuV-IA and 32 full length genomic sequences fromGenbank (Fig. 1B).
Phylogenetic analysis indicated that MuV-IA is most closely related to
the sequence of MuV Du/CRO05, a genotype G virus, which was
isolated in Croatia in 2005 (Santak et al., 2006). A comparison of the
predicted amino acid sequences between the protein coding regions
of MuV-IA and Jeryl Lynn vaccine (major component) showed that
while NP, M and L protein sequences are highly conserved with an
identity of over 98%, there was more divergence among V, P, F, SH andHN proteins (Fig. 1C). The predicted SH protein sequences had only
85% identity.
Generation of an infectious cDNA clone for MuV-IA
To be able to study the pathogenesis of MuV-IA, a reverse genetics
system was derived. Because RNA viruses exist as a quasi-species, the
consensus sequence of the genome was used as the base for the
recombinant MuV. A plasmid containing a mini-genome with
luciferase (Luc) reporter gene for mumps virus (pT7-MuV-Mini-Luc)
similar to the PIV5 mini-genome expressing plasmid was constructed
using rMuV-IA trailer and leader sequences (data not shown) (Lin et
al., 2005). In addition, plasmids encoding NP, P and L in the pCAGGS
vector have been obtained and conﬁrmed by sequencing. To test the
functionality of the plasmids, the plasmids were transfected into BSR-
T7 cells. At 2 dpi, the cells were harvested and Luciferase (Luc) assays
were performed. Luc activity was detected in the cell transfected with
all plasmids, not ones missing P or L, indicating that the plasmids
expressed functional P and L proteins (data not shown). RT-PCR was
conducted to amplify DNA fragments representing the complete
genome and inserted into individual plasmid vectors before being
assembled into a full-length genome. The plasmid with the full length
genome of MuV-IA expressed under the control of a T7 (pMuV-IA)
promoter (pMuV-IA) was similar to the plasmid used to generate
infectious PIV5 (He et al., 1997). pMuV-IA had changes in two
nucleotides within the L ORF compared with consensus sequence of
MuV-IA at positions of 11863 (T to C) and 12028 (C to T). However,
neither of these nucleotide changes resulted in changes in the
predicted L protein sequence. A recombinant MuV (rMuV-IA) was
rescued using the plasmid containing the full-length genome of MuV-
IA. BSRT-7 cells were co-transfected with pMuV-IA and plasmids
expressing viral RNA polymerase components. Individual plaques
were selected and ampliﬁed in Vero cells. The entire genome of the
rescued virus was sequenced and found to match the input cDNA
genome sequence (data not shown).
To compare time course of the growth of rMuV and MuV-IA, a
multi-cycle growth assay was performed (Fig. 2A). Both viruses grew
to similar peak titers in Vero cells. Viral titers in the supernatant of the
infected cells increased exponentially during the ﬁrst 2 days after
infection, and reached a titer of 107 pfu/ml at 48 hpi. We also
compared the growth of both viruses in HeLa cells (a human cell line),
MDBK cells (a bovine cell line), and L929 cells (a murine cell line) and
did not observe any obvious differences between these two viruses
(data not shown). The viral protein expression levels in cells were also
examined using Western blot (Fig. 2B) and the protein levels were
similar at different time points after infection, indicating that the
replication of rMuV resembles MuV-IA in tissue culture cells.
In addition, we rescued infectious recombinant viruses expressing
either EGFP or Renila Luciferase (RL) protein as an extra gene. pMuV-
EGFPwas constructed by inserting an EGFP gene, ﬂanked by gene start
(GS) of SH and gene end (GE) of NP, between F gene and SH gene in
pMuV-IA, pMuV-RL was constructed through substitution of coding
sequence of EGEP with that of renilla luciferase (RL) in pMuV-EGFP.
Expression of EGFP or RL in the infected Vero cells was detected
(Figs. 2C, D).
Rescue of a recombinant mumps virus lacking the SH ORF
To study the function of the SH protein of MuV, 156 nucleotides in
the SHgeneopen reading frame(ORF)of the SHgeneweredeleted from
pMuV-IA. The truncated SH ORF contained a short ORF encoding 5
amino acid residues ﬂanked by the original SH ORF start and gene end
(pMuV-IAΔSH, Fig. 3A). An infectious MuV lacking the SH ORF was
rescued (rMuVΔSH) (Figs. 3B and C) and the genome was sequenced,
which matched the input cDNA sequence (data not shown). The
rMuVΔSH genomewas of 15,228 nt in size, complying with “the rule of
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express a SH protein and that rMuVΔSH did not, cell lysates of infected
Vero cells were examined by immunoblotting with anti-SH as well as
anti- NP and anti-P (Fig. 3D). SH was detected in MuV-IA and rMuV-
infected cells, but not in rMuVΔSH-infected cells, conﬁrming the lack of
the SH protein expression in rMuVΔSH-infected cells.A
B
CAnalysis of rMuV and rMuVΔSH
To investigate the growth rate of rMuVΔSH, a multiple-cycle
growth curve and protein expression levels were examined in Vero
cells, and the titers of the viruses released from rMuVΔSH-infected
Vero cells remained similar to rMuV-infected Vero cells at all time
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expression levels were compared using Western blot, the protein
levels of NP and P in rMuVΔSH and rMuV-infected cells were similar
(Fig. 4B), indicating that the SH ORF was not essential for viral gene
expression, or virus release in Vero cells, consistent with the previous
ﬁndings (5). The HN gene is downstream of the SH gene. To examine
whether there is any signiﬁcant impact of the deletion of the SH ORF
on the expression level of HN, expression levels of HN and NP of
infected cells were examined using ﬂowcytometry. As shown in
Fig. 4C, relative expression level of HN in rMuV-infected cells and in
rMuVΔSH-infected cells were similar, suggesting that the deletion of
the SH ORF sequence did not affect expression of the HN protein.
Furthermore, mRNA expression levels of HN were examined using
real-time RT-PCR. No signiﬁcant difference was observed between
rMuV and rMuVΔSH (Fig. 4D). Interestingly, rMuVΔSH formed larger
plaques in Vero cells compared to rMuV (Fig. 4A).
rMuVΔSH induced cytopathic effect in L929 cells
We compared infection of Vero, MDBK and HeLa cells with
rMuVΔSH and rMuV. At 1 day post infection, there were no
observable differences in rMuVΔSH- or rMuV-infected Vero and
MDBK cells. Previous studies in our lab showed that the SH ORFs of
PIV5 and RSV played a role in blocking TNF-α signaling. To test the
hypothesis that mumps virus SH ORF has a role in regulating the
TNF-α signaling pathway, we investigated the phenotype of
rMuVΔSH in L929 cells, which undergo apoptosis after TNF-α
treatment. rMuVΔSH infection led to signiﬁcantly more cell death
than infections with rMuV or wtMuV. The phenotype was evident at
2-day post infection (Fig. 5B). To investigate whether the cytopathic
effects (CPE) observed in rMuVΔSH infected L929 cells was caused by
apoptosis, TUNEL assay was performed. At 1 dpi, infection with
rMuVΔSH resulted in a higher percentage of infected cells with
apoptosis than rMuV (Fig. 5C), indicating that the lack of SH led to
increased apoptosis in infected cells.
TNF-α played a critical role in rMuVΔSH-induced apoptosis
To test whether apoptosis in rMuVΔSH infected L929 cells resulted
from an elevated TNF-α, we examined activation of NF-κB in
rMuVΔSH-infected L929 cells by examining nuclear translocation of
p65, a key subunit of NF-κB. NF-κB factors are localized in the
cytoplasm. On activation, for example by TNF-α stimulation, p65 is
translocated into the nucleus (Baud and Karin, 2001). A higher level of
p65 nuclear localization was observed in rMuVΔSH-infected L929
cells (Fig. 6A), indicating activation of NF-κB. To investigate whether
the production of TNF-α was increased in rMuVΔSH-infected cells,
supernatants of infected were collected and levels of TNF-α were
measured using ELISA. TNF-α production level was up regulated in
rMuVΔSH-infected cells (Fig. 6B). To determine whether the
increased TNF-α played a role in increased apoptosis in rMuVΔSH-
infected cells, the infected cells were treated with neutralizing
antibody against TNF-α. Anti-TNF-α reduced CPE in rMuVΔSH-
infected cells, while the control antibody had no effect (Fig. 6C),
indicating that TNF-α played a critical role in rMuVΔSH induced cellFig. 1. Analysis of MuV-IA genome. (A). Alignment of the SH proteins. Sequences of three stra
UK96* and UK01-22 for only 5 nucleotides and 2 amino acids respectively. The transmembra
TMHMMserver v.2.0 (CBS;Denmark). (B). Sequence comparison ofdifferentmumpsviruses. Th
alignedwithgenome sequenceofMuV-IAusingMEGA4version4.0.2. The32MuVStrainswere (
Biken (AF314561), 87–1005 (AF314562), MuV(2001) (AF314559), Urabe 1004-10/2 (FJ3751
Miyahara (1992) (2) (AB040874), Y213(AB576764), Dg1062/Korea/98 (32172464), L3/Ru
(AY685920), 9218/Zg98(299766355), Novosbrisk genotype C (50404164), PetroNov genotype
SP-A (FJ556896), SP (EU884413), SP(2006) (DQ649478), JL2 (AF3452901), Jeryl Lynn sub strain
(AF201473), JL1 (FJ211586), RIT4385 (FJ211585), RIT4385(2) (FJ211584). (C). Sequence compa
sequences of NP, P/V (encoding P protein and V protein), M, F, SH, HN and L of MuV-IA and Jery
identities and amino acid identities were shown above. * The SH genes were aligned using MEdeath. This was conﬁrmed with TUNEL assay (Fig. 6D). At 1 dpi, with
control antibody treatment, rMuVΔSH induced almost 4-fold higher
apoptotic rate than rMuV. Treatment of anti-TNF-α antibody
effectively blocked cell death in infected cells (Figs. 6C, D).
SH of MuV-IA blocked TNF-α signaling in vitro
To investigate whether MuV-IA SH expressed alone can block
TNF-α signaling, a plasmid encoding SH of MuV-IA was co-transfected
with a NF-κB promoter-luciferase reporter system into L929 cells. At
1-day post transfection, cells were treated with TNF-α. TNF-α
signaling was blocked by SH of MuV-IA as well as SH of PIV5, but
not by NP of MuV-IA (Fig. 7A) or the sequence of the SH ORF (Fig. 7B),
indicating that the SH protein can block TNF-α-mediated signaling.
rMuVΔSH was attenuated in vivo
MuV is a human virus and there is no ideal animal model in which
to study viral pathogenesis. Intracerebral injection of MuV into
newborn rats has been used to compare the relative pathogenecities
of different strains of MuV (Rubin et al., 2005). To compare the
neurotoxicity of the viruses, rMuV or rMuVΔSH was injected
intracerebrally into brains of newborn rats. Relative neurotoxicity
score was calculated based on relative severity of hydrocephalus. As
shown in Fig. 8, rMuVΔSH had a lower neurotoxicity score than rMuV,
indicating that deletion of the SH ORF resulted in attenuation in vivo.
Discussion
Immunization against MuV is a part of a 2-dose MMR (mumps,
measles and rubella) vaccine regimen that is administrated to
children at 1 and 5 years of age in the U.S. Even with a two-dose
vaccination schedule, large outbreaks have occurred in vaccinated
populations. Here, we describe the rescue of a wild-type mumps virus
that is representative of the strain associated with recent outbreaks in
the U.S. and Europe. This has enabled us to begin to explore the
pathogenesis of MuV using reverse genetics. In this report, we
described the potential role of the SH protein in regulating TNF-α, and
we found that the deletion of the SH ORF resulted in attenuation in
vivo, indicating that SH plays a role in viral pathogenesis. The
attenuation of rMuVΔSH in vivo suggests that deleting the SH ORF can
be a possible strategy to develop attenuated mumps strains.
Recombinant MuVs expressing foreign genes such as GFP and RL
have been obtained, and interestingly, the expression level of RL in
rMuV-RL in Vero cells remained relatively high after 20 passages (data
not shown), indicating that MuV can possibly be used as a vector.
The SH protein of paramyxoviruses was ﬁrst identiﬁed in PIV5-
infected cells (Hiebert et al., 1985). A similar gene was predicted
basing on sequence analysis of the Enders strain of MuV. However,
due to a mutation in the intergenic sequence of the putative SH gene,
the SH protein of the Enders strain MuV is not expressed in infected
cells (Takeuchi et al., 1991). Thus, the SH protein of MuV has never
been detected in MuV-infected cells. Wilson et al. (2006) replaced the
SH ORF within the genome of PIV5 with the SH ORF of MuV Enders
strain and found that the MuV SH can functionally replace the SH ORFins, Glouc1/UK96, UK01-22 and MuV-IA were shown. MuV-IA was different from Glouc1/
ne domain of mumps virus SH protein, outlined in rectangular box, was predicted using
egenomesequences of 32 strainsofmumpsviruseswere obtained fromNCBIGenbankand
accessionnumbersare given in thebrackets): 87–1004(AF314560), SIPAR02(AF314558),
77), Urabe Gw7 (FJ375178), Hoshino (AB470486), Miyahara (1992) (NC_002200), MuV
ssia/Vector (AY508995), L-Zagreb master seed (AY685921), L-Zagreb vaccine strain
H (AY681495), 88–1961 (AF467767), Glouc1/UK96(AF280799), Du/CRO05 (EU370207),
(FN31985), Enders (GU9800521), Jeryl Lynnmajor component (AF338106), MuV(2000)
rison betweenMuV-IA and Jeryl Lynn (JL) strain (major component). The gene and protein
l Lynn live vaccine major componentwere aligned using NCBI BLAST program. Nucleotide
GA 4.0.2.
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Fig. 2. Analysis of rMuV, rMuV-EGFP and rMuV-RL. (A). Growth rate of rMuV. rMuV was obtained by transfecting BSRT-7 cells with pMuV-IA, pCAGGS-NP, pCAGGS-P and pCAGGS-L
as described in the Material and Methods. Growth rates of rMuV (empty square) and MuV-IA (ﬁlled triangle) were compared as described in the Material and Methods. (B). Viral
protein expression levels of rMuV and MuV-IA. 6 well plates of Vero cell were infected with mock, rMuV or MuV-IA at a MOI of 0.5. Cell lysates were subjected to immunoblotting
with anti-NP, P or V. (C). Rescue of rMuV-EGFP. rMuV-EGFP was rescued in a similar manner as described for rMuV. Vero cell in 6 well plates were infected with mock or rMuV-EGFP
at a MOI of 0.05 and photographed at 2 dpi. (D). Rescue of rMuV-RL. rMuV-RL was recovered from cloned DNA as described for rMuV. 24 well plates of Vero cell were infected with
mock or rMuV-RL at MOI of 0.1. At 2 dpi, cells were assayed for renilla luciferase activity.
130 P. Xu et al. / Virology 417 (2011) 126–136of PIV5 (Wilson et al., 2006). Thus, it is thought that the function of
MuV SH is the same as the function of the SH ORF of PIV5, a closely
related paramyxovirus. In this work, the expression of SH was
detected in MuV-infected cells for the ﬁrst time, conﬁrming the
existence of the SH protein in MuV-infected cells. Furthermore, takingA
B C
D
Fig. 3. Generation of a MuV lacking SH (rMuVΔSH). (A). A schematics of rMuVΔSH. The
(underlined). (B). Conﬁrmation of rMuVΔSH by RT-PCR. After plaque puriﬁcation, viral RNA
were used to perform a PCR to conﬁrm the deletion. Lane 1 and Lane 6 are 100 bp and 1 kb DN
and 5 are PCR products from rMuVΔSH, rMuV and wtMuV-infected cells respectively. (C).
sequence is underlined. (D). Expression of SH in MuV-IA, rMuV and rMuVΔSH-infected cells.
were subjected to immunoblotting with anti-NP, P or SH.advantage of the new reverse genetics system, a recombinant MuV
lacking the SH ORF (rMuVΔSH) was obtained and analyzed.
One interesting observation was that rMuVΔSH produced larger
plaques. A possible explanation is that the deletion of the SH ORF
resulted in a virus that promotes cell-to-cell fusion better than theSH ORF was replaced with a 5 amino acid coding sequence containing an Nhe I site
was extracted and was subjected to RT-PCR, in which two primers ﬂanking the SH gene
A ladder respectively; Lane 2 is the negative control—PCRwithout polymerase. Lane 3, 4
Conﬁrmation of rMuVΔSH by sequencing. PCR products were sequenced. The inserted
Vero cells were mock infected or infected with MuV-IA, rMuV or rMuVΔSH. Cell lysates
131P. Xu et al. / Virology 417 (2011) 126–136wild type virus. Because there was no change of total number of ORFs
or the overall order of genes, we expect that the relative amounts of
viral mRNAs and the expression levels of viral proteins of rMuVΔSH
should be similar to those of wild type virus (Figs. 4B, C and D). Thus, it
is unlikely that the bigger plaque formation by rMuVΔSHwas due to a
higher level of viral protein expression. Further, we have performed a
fusion assay using cells transfected with MuV HN and F in the
presence or absence of MuV SH, and did not observe any difference in
the extent of cell-to-cell fusion (data not shown), suggesting that the
SH does not have a role in promoting cell-to-cell fusion. We speculate
that the larger plaques formed by rMuΔSH are due to a higher level of
induction of cell death by rMuVΔSH. The viruses infected cells at the
same rate; however, the cells infected by rMuVΔSH induced more cell
death than rMuV resulting in more rapid cell death at the edge of a
plaque.
It is possible that the mRNA of from some ORFs may have biologic
functions. For example, the mRNA of the L ORF of PIV5 is capable of
activating IFN-β expression (Luthra et al., 2011). In this work, we
deleted the ORF of SH and we cannot differentiate the function of the
polypeptide encoded by the SH ORF from SH mRNA itself. While the
SH polypeptide was needed to block TNF-α mediated signaling, not
the sequence of the SH ORF, and we favor a critical role of the SHHours post infection
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Fig. 4. Growth rates and viral protein expression of rMuVΔSH and rMuV. (A). Growth rates of
(empty square) at MOI of 0.01. Supernatants were used for plaque assay. (B). Viral protein e
infected with rMuVΔSH or rMuV at aMOI of 0.5. (C). HN expression level in rMuVΔSH and rM
MOI of 0.5. Cells were collected at 24 hpi and expression levels of total HN and NP were ex
calculated. Y-axis represents the relative ratio of MFI of HN normalized by MFI of NP. (D). H
rMuVΔSH or rMuV-infected Vero cells, reverse transcribed with oligodT and used for real tim
mRNA level. Y-axis represents ratio of HN mRNA verses F mRNA.polypeptide in mumps virus pathogenesis; however, it is possible that
the small mRNA potentially expressed from the deleted SH gene could
have contributed to the phenotype of rMuVΔSH.
The reduced neurotoxicity of rMuVΔSH in neonatal rat brain
indicates that the SH ORF plays a critical role in viral pathogenesis. We
propose that infection with rMuVΔSH induced a higher level of pro-
inﬂammatory cytokine expression, resulting in a more rapid resolu-
tion of infection, thus limiting damage in the infected brain. A better
animal model for studying mumps virus pathogenesis will be highly
desirable to understand the exact mechanism of the reduced
neurotoxicity.
Material and methods
Plasmids, viruses and cells
All molecular cloning was conducted according to standard
procedures as previously described (He et al., 1997). MuV-IA NP, P
and L genes were cloned into the pCAGGS expression vector (Niwa et
al., 1991). MuV-IA SH gene was cloned into the pCAGGS expression
vector. MuV-IA SH (stop codon) was constructed by introducing three
continues stop codon sequence into the SH ORF, 6 nucleotides0 24 48 72 0 24  48 72  Mock
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132 P. Xu et al. / Virology 417 (2011) 126–136downstream of the start codon. Construction of MuV-IA full-length
cDNA in pUC19 was analogous to the PIV5 reverse genetics system
(He et al., 1997). To construct pMuVΔSH, the region of the SH ORF
from the 4th amino acid to the 57th (156 nt) was substituted with a
short 6 nucleotide sequence designed to facilitate subcloning and to
maintain the length of the genome a multiple of six (known as the
“rule of six”). pMuV-EGFP and pMuV-RL were constructed by
inserting either an EGFP or a renilla luciferase gene between F and
SH gene ﬂanked by F gene start and SH gene end. Primer sequences,
detailed cloning strategies and entire cDNA sequences of MuV are
available upon request.
To rescue an infectious virus from cDNA, plasmid (5 μg) containing
a full-length genome or a mutated MuV genome was co-transfected
with plasmids pCAGGS-L (1 μg), pCAGGS-NP (1.5 μg) and pCAGGS-P
(200 ng) into BSRT-7 cells. Usually 4 to 7 days post-transfection,
syncytia formation could be observed in transfected BSRT-7 cells.
Supernatants were plaqued in Vero cells. Plaques could be visualized
at 4 to 7 dpi. One or two plaques from each independent rescue were
ampliﬁed in Vero cells and their genomes were sequenced.
Vero, HeLa, MDBK and L929 cells were maintained in Dulbecco's
modiﬁed Eagle medium (DMEM) with 10% fetal bovine serum (FBS)
and 1% penicillin-streptomycin (P/S)(Mediatech Inc., Holu Hill, FL),
BSRT-7 cell were maintained in DMEM supplemented with 10% FBS,
1% P/S and 10% tryptose phosphate broth (TPB) plus G418 at 400 μg/ml.
Cells were cultured at 37 °C with 5% CO2 and passed the day before
infection or transfection at appropriate dilution factors to archivedMock                      rMuVA
B
1 dpi
2 dpi
Mock rMuV rMuVΔSH
MDBK
HeLa
Vero
Fig. 5. Induction of cell death by rMuVΔSH. (A). Cytopathic effects of rMuVΔSH or rMuV in tis
with rMuVΔSH or rMuV at MOI of 0.01 and photographed at 1 dpi. (B). Cytopathic effects
rMuVΔSH, or rMuV at a MOI of 3 and were photographed at 1 dpi and 2 dpi. (C). rMuVΔSH
ﬂoating cells and attached cells were collected, ﬁxed, permeabilized and used for TUNEL as80–90% conﬂuence the next day. For virus infection, cells were
infected with viruses in DMEM plus 1% bovine serum albumin (BSA)
at MOI of 0.01, 3 or 5 and incubated for 1 to 2 h at 37 °C with 5% CO2.
The culturing medium was then replaced with DMEM supplied with
2% FBS and 1% P/S. For transfection, cells were transfected with
plasmids using PLUS™ and Lipofectamine™ reagents from Invitro-
gen following the manufacturer provided protocol.
MuV-IA (MuV/Iowa.US/2006) was isolated at the Iowa Hygenic
Laboartory from a buccal swab obtained from a mumps case during
the early phase of the outbreak in 2006. Genotype analysis was
performed at the CDC (Rota et al., 2009) and the accession number for
the SH sequence is DQ661745. All mumps viruses were grown in Vero
cells andwere harvested 4 to 7 dpi. Virus titers weremeasured in Vero
cells by plaque assay followed by Giemsa staining as described before
(He and Lamb, 1999; He et al., 1997).
Sequencing of viruses
Viral RNA was extracted from cell culture supernatants using
QIAamp® viral RNA extraction mini kit from QIAGEN following
manufacturer's protocol. Isolated total RNA was reverse transcribed
into cDNA using Super Script® III reverse transcriptase from
Invitrogen with random hexamers. Synthesized cDNA was then
served as templates for PCR using mumps virus genome speciﬁc
primers and Taq polymerase from Invitrogen. 15 sets of primers, each
contained a forward and a reverse primer, were designed as to dividerMuVΔSH
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Fig. 6. The role of TNF-α in rMuVΔSH-mediated cell death. (A). rMuVΔSH infection activated P65 in L929 cells. L929 cells on glass cover slips were infected with mock, rMuVΔSH or
rMuV at aMOI of 10. At 1 dpi, L929 cells on the cover slips were stained with anti-P65. (B). rMuVΔSH infection in L929 cells induced TNF-α production. L929 cells weremock infected
or infected with rMuVΔSH, or rMuV at a MOI of 5. TNF-α in the media was measured using ELISA. (C). Treatment with anti-TNF-α antibody reduced CPE in rMuVΔSH infected L929
cells. L929 cells were mock infected or infected with rMuVΔSH or rMuV at a MOI of 5. Cells were cultured in media containing TNF-α neutralizing antibody or control antibody and
were photographed at 1 dpi. (D). TNF-α antibody treatment inhibited apoptosis in rMuVΔSH infected L929 cells. L929 cells in 6 well plates were infected and treated as in C. At 1 day
and 2 days post infection, cells were collected and used for TUNEL assay.
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the subsequent sequencing of the PCR products (Li et al., 2011).
Leader and Trailer sequences were sequenced following standard
protocol of Rapid Ampliﬁcation of cDNA Ends (RACE) (Li et al., 2011).
Primer sequences are available upon request.
Generation of monoclonal and polyclonal antibodies against mumps NP,
P and SH
To generate monoclonal antibodies against MuV-IA, the virus was
grown in Vero cells. The medium of infected Vero cells was collected,
and clariﬁedwith low-speed centrifugation at 3 K rpm for 10 min. The
clariﬁedmedia containing viruswas overlaid onto a 10 ml 20% sucrose
solution and centrifuged at 40 K rpm for 1.5 h at 4 °C. The pellet was
resuspended in 0.5 ml 10× PBS, mixed with 1.3 ml 80% sucrose
solution and overlaid by a decreasing sucrose gradient from bottom totop: 1.8 ml 50% sucrose solution and 0.6 ml 10% sucrose solution. The
sucrose gradient with virus at the bottomwas centrifuged at 45 K rpm
for 3 h at 4 °C. 1 ml fractions were collected, mixed with 10 ml 1× TEN
buffer (100 mM NaCl, 10 mM Tris-base, 1 mM EDTA) and spun down
at 40 K rpm for 1.5 h at 4 °C. The pellet containing virus was
suspended in 50 μl of 1× TEN buffer plus 1% NP-40 and used for
generation of mouse hybridoma cells. Mouse hybridoma cells
generating monoclonal antibodies against MuV-IA NP and P were
engineered by the core facility in the Pennsylvania State University.
The hybridomas were culture in D-MEM supplied with sodium
pyruvate, with addition of 20% FBS and 0.1% Gentamicin at 37 °C with
5% CO2.
To generate polyclonal antibodies against MuV-IA SH, two
peptides (N-terminal MPAIQPPLYLTFLLC and C-terminal
CYQRSFFHWSFDHSL) were purchased from GenScript Corporation.
Two peptides (QFIKQDETGDLIETC and CSRPDNPRGGHRREW) were
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Fig. 7.MuV-IA SH inhibited TNF-α activation of NF-κB. L929 cells were transfected with
a reporter plasmid (pκB-TATA-FL) and pCAGGS-MuV SH, pCAGGS-PIV5 SH or pCAGGS-
MuV-NP (panel A). At 1 day post-transfection, cells were treated with TNF-α at 10 ng/ml
for 4 h and then assayed for ﬁre ﬂy luciferase activity. Similarly, the effect of the sequence
of the SH ORF was examined using a plasmid encoding the SH ORF sequence without
expressing the SH polypeptide due to in-frame stop codon insertion downstream of the
start codon of the SH ORF (Panel B).
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Corporation) in rabbits.
Treatment of infected cells with anti-TNF-α
L929 cells in 6well plates were infectedwith rMuVΔSH or rMuV at a
MOI of 5 and cultured in DMEM supplemented with 2% FBS and 1% P/S
with neutralizing anti-TNF-α antibody or control antibody (BD
Pharmingen) at 50 μg/ml for 1 or 2 days (9). At 1 day or 2 dpi, cells
were photographed with a microscope with a digital camera, and then
collected for MuV-NP staining or TUNEL assay.0
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Fig. 8. Neurotoxicity of MuVΔSH in vivo. Newborn rats were infected intracerebrally
with rMuV or rMuVΔSH. The animals were sacriﬁced at 30 days post infection. The
brains of the animals were sectioned, stained and neurotoxicity scores were calculated
based on relative hydrocephalus score as described in the Material and Methods.Flow cytometry and TUNEL assay
Flow cytometry was performed as previously described (Timani et
al., 2008). L929 cell in 6 well plates were infected with rMuVΔSH or
rMuV or mock infected at MOI of 3 or 5. At 1 or 2 dpi, attached cells
were trypsinized and combined with ﬂoating cells in the culture
media. Cells were centrifuged and resuspended in 0.5% formaldehyde
in phosphate buffered saline (PBS) for 1 h at 4 °C. The ﬁxed cells were
then washed with PBS, permeabilized in 50% FCS-50% DMEM plus
three volumes of 70% ethanol overnight. Permeabilized cells were
subjected for either TUNEL staining for apoptotic cells according to
manufacturer's protocol or MuV-NP staining for infection rate. When
cells were for NP staining, monoclonal MuV-NP antibody was diluted
to 1:200 followed by PE anti-mouse secondary antibody staining at a
dilution factor of 1:100.
Vero cells were mock infected or infected with rMuVΔSH or rMuV
at a MOI of 0.5 or 0.01. At 24 or 48 hpi, attached cells were collected in
combination with ﬂoating cells, ﬁxed. For HN surface staining, cells
were directly stainedwith anti-HN at a dilution factor of 1:50; for total
staining of HN and NP staining, ﬁxed cells were permeabilized with
0.1% saponin in PBS and stained with anti-NP at a dilution factor of
1:200 or anti-HN at a dilution factor of 1:50.
Assays for detection of activation of NF-κB
L929 cells on glass cover slips in 6 well plates were infected with
rMuVΔSH, or rMuV atMOI of 0.01, or mock infected. At 2 dpi the cover
slips werewashedwith PBS, and ﬁxed in 0.5% formaldehyde. The ﬁxed
cells were permeabilized with PBS plus 0.1% saponine and then
incubated with mouse anti-P65 (Santa Cruz Biotechnology) in PBS
with 0.1% saponine followed by secondary FITC labeled goat anti-
mouse antibody (Jackson Laboratory). The cells were photographed
using a ﬂuorescence microscope with a digital camera.
The NF-κB reporter assay system was performed as described
previously (Wilson et al., 2006). L929 cells were plated into 24 well
plates and transfected using PLUS™ and Lipofectamine™ reagents
with either empty vector, pCAGGS-MuV SH, pCAGGS-MuV SH(stop),
pCAGGS-PIV5 SH or pCAGGS-MuV NP, plus a pκB-TATA-Luc (a
reporter plasmid containing a NF-κB promoter region followed by
TATA box enhancer and a ﬁreﬂy luciferase gene) and a pCAGGS-RL (a
transfection control plasmid expressing renilla luciferase protein). On
the second day post transfection, half of the cells were treated with
TNF-α (Alexis, San Diego) at a concentration of 10 ng/ml in Optima
(Invitrogen) for 4 h at 37 °C with 5% CO2; half of the cells were treated
with Optima only. Cells were then lysed with 100 μl 1× passive lysis
buffer (Promega, Madison, WI) and 10 μl of the lysate were subjected
for dual luciferase assay using a dual luciferase assay kit (Promega,
Madison, WI). The ratio of TNF-α stimulated cells over no TNF-α
stimulation is used as “induction of luciferase activity”.
Immunoblotting
Vero cells in 6 well plates at about 90% conﬂuence were infected
with mock, MuV-IA, rMuV or rMuVΔSH at a MOI of 0.05. Cells were
collected and lysed at 0 h, 24 h, 48 h, or 72 h post-infection in 0.5 ml
WCEB buffer (50 mM Tris–HCl PH 8.0, 120 mM NaCl, 0.5% NP-40,
0.00076% EGTA, 0.2 mM EDTA, 10% Glycerol) with a mixture of
protease inhibitors as described before (Luthra et al., 2008). Cell
lysates were brieﬂy centrifuged to remove cell debris. Cell lysates
were loaded into 10% or 17.5% polyacrylamide gel and subjected for
SDS-PAGE. Protein were transferred to Immobilon-FL transfer
membrane (Millipore), incubated with primary antibody (anti-MuV
SH 1:250, anti-MuV V 1:500, anti-MuV NP 1:5000, anti-MuV P
1:2000) and corresponding secondary antibodies conjugated to
horseradish peroxidase, and detected by Amersham ECL™ western
blotting detection kit (GE Healthcare).
135P. Xu et al. / Virology 417 (2011) 126–136Time course of rMuVΔSH, rMuV and MuV-IA infection in cell culture
Cells in 6 cm plates were infected with MuV-IA, rMuV, or
rMuVΔSH at MOI of 0.01. 100 μl of supernatant were collected at
0 h, 24 h, 48 h, 72 h postinfection and frozen down at −80 °C
supplemented with 1% BSA. Virus titers were determined by plaque
assay using Vero cells in 24 well plates in triplicates. After 1 to 2 h
incubation with the viruses, growth media were changed into semi-
solid DMEM with 2% FBS, 1% P/S and 1% low melting point agarose. 4
to 7 dpi, 24 well plates of Vero cells were stained with Giemsa stain
and plaques were counted.
Enzyme-linked immunosorbent assay (ELISA) of TNF-α
L929 cells in 6 well plates were infected with mock, rMuV or
rMuVΔSH at MOI of 5. Culturing media were collected at 1 dpi, 2 dpi
and 3 dpi. The amount of TNF-α secreted into the culturingmedia was
measured using amurine TNF-α detection kit (Amersham Pharmacia)
following the procedures described before (Li et al., 2011).
Real time RT-PCR
Vero cells were mock infected or infected with rMuVΔSH or rMuV
at a MOI of 0.005. Viral RNA was extracted from infected cells at 4 dpi
using QIAGEN RNeasy mini kit and reverse transcribed into cDNA
using Oligo-dT as primers.
MuV F and HN mRNA speciﬁc FAM tagged probes were purchased
from Applied Biosystems™. Real time PCR was assembled using
TaqMan® Gene Expression Master Mix, according to manufacturer's
protocol. Ratio between HN mRNA verses F mRNA was calculated
using ΔCt.
Examination of MuV neurotoxicity
The rat neurotoxicity test was performed as described before
(Rubin et al., 2000). Newborn rats were inoculated intracerebrally
with 100 pfu of rMuV (n=36), or rMuVΔSH (n=24) in 20 μl EMEM.
Animals were sacriﬁced at 1 month after injection and the brainswere
removed, immersionﬁxed and embedded in parafﬁn. One 10 μm
sagittal section at a constant distance from the anatomical midline
from each hemisphere of brain was selected, and stained with
haematoxylin and eosin. The neurotoxicity score was calculated based
on the cross-sectional area of the brain (excluding the cerebellum) as
a percentage of the lateral ventricle on tissue sections from paired
brain using Image- Pro Plus image analysis software (Media
Cybernetics). The neurotoxicity score was deﬁned as the mean ratio
(percentage) of these two measurements on each of the two tissue
sections per rat brain. Any rats with signs of pain or distress prior to
the planned 1 month end point were humanely euthanized immedi-
ately and included in analyses. The NIH Guidelines for the Care and
Use of Laboratory Animals were strictly adhered to throughout.
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